# Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis

> **NCT07047339** · PHASE2,PHASE3 · RECRUITING · sponsor: **Changhai Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Colitis
- IBD (Inflammatory Bowel Disease)
- Probiotic Intervention

## Interventions

- **DRUG:** Probiotics 6600
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07047339
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07047339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07047339, "Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07047339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*